News Releases

Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology

July 14, 2026

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

July 6, 2026

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

June 29, 2026

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

June 26, 2026

Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

June 11, 2026

Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance

June 1, 2026

Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy

May 11, 2026

Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV

May 1, 2026

Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology

April 29, 2026

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting

April 22, 2026

1
2
3
4
5
6
7
8
9
10
...33
Next »

Latest News & Events

Jul 14, 2026

Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology

Read More...

Jul 6, 2026

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

Read More...

Jun 29, 2026

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

Read More...